Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19-Reference-Cited by-同舟云学术

Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19

Published:2024-06-03 Issue:5 Volume:96 Page:517-522
ISSN:2309-5342
Container-title:Terapevticheskii arkhiv
language:
Short-container-title:Terapevticheskii arkhiv

Author:

Sabitov Alebai U.¹^ORCID,Lioznov Dmitry A.²³^ORCID,Zhdanov Konstantin V.⁴^ORCID,Tikhonova Elena P.⁵^ORCID,Esaulenko Elena V.⁶^ORCID,Kovtun Olga P.¹^ORCID,Kuznetsov Pavel L.¹⁷^ORCID,Sorokin Pavel V.⁸^ORCID

Affiliation:

1. Ural State Medical University

2. Smorodintsev Research Institute of Influenza

3. Pavlov First Saint Petersburg State Medical University

4. Pediatric Research and Clinical Center for Infectious Diseases

5. Prof. V.F. Voino-Yasenetsky, Krasnoyarsk State Medical University

6. Saint Petersburg State Pediatric Medical University

7. City Clinical Hospital No. 40

8. “Pharmaviron” LLC

Abstract

Aim. To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. Materials and methods. The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial. Results. The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established. Conclusion. As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.

Publisher

Consilium Medicum

Link

https://ter-arkhiv.ru/0040-3660/article/viewFile/632975/pdf

Reference12 articles.

1. WHO Director-General's opening remarks at the media briefing – 5 May 2023. Available at: https://www.who.int/ru/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023. Accessed: 05.04.2024.

2. COVID-19 epidemiological update – 15 March 2024. Available at: https://www.who.int/publications/m/item/covid-19-epidemiological-update-15-march-2024. Accessed: 05.04.2024.

3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России, версия 18 от 26.10.2023. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/%D0%92%D0%9C%D0%A0_COVID-19_V18.pdf. Ссылка активна на 05.04.2024 [Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii Minzdrava Rossii, versiia 18 ot 26.10.2023. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/%D0%92%D0%9C%D0%A0_COVID-19_V18.pdf. Accessed: 05.04.2024 (in Russian)].

4. Meta-analysis of randomized controlled clinical trials of Riamilovir eﬃcacy in the etiotropic therapy of acute respiratory viral infection